Evidence map›Paper›PMID 30181285›Full record

ArticleProceedings of the National Academy of Sciences of the United States of America2018

Inhibition of cIAP1 as a strategy for targeting c-MYC-driven oncogenic activity.

Haoyan Li, Yanjia Fang, Chunyi Niu, Hengyi Cao, Ting Mi, Hong Zhu, Junying Yuan, Jidong Zhu

Open access · bronzeAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Proceedings of the National Academy of Sciences of the United States of America, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 11 papers.

0numbers the graph read from it
0cells of the map it votes in
11citing papers in PubMed
1.4field-weighted citation impact, top 18% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

11 citing papers in PubMed, 25 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Regulation of apoptosis by ubiquitination in liver cancer.American journal of cancer research · 2023
    Review
  5. Review
  6. Article
  7. Article
  8. Article
  9. Article
  10. Article
  11. Getting MAD at MYC.Proceedings of the National Academy of Sciences of the United States of America · 2018
    Article
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

8 authors at 2 institutions in 2 countries.

Haoyan LiInterdisciplinary Research Center on Biology and Chemistry, Center for Excellence in Molecular Synthesis, Shanghai Institute of Organic Chemistry, Chinese Academy of Sciences, 201203 Shanghai, China.
Yanjia FangInterdisciplinary Research Center on Biology and Chemistry, Center for Excellence in Molecular Synthesis, Shanghai Institute of Organic Chemistry, Chinese Academy of Sciences, 201203 Shanghai, China.
Chunyi NiuInterdisciplinary Research Center on Biology and Chemistry, Center for Excellence in Molecular Synthesis, Shanghai Institute of Organic Chemistry, Chinese Academy of Sciences, 201203 Shanghai, China.
Hengyi CaoInterdisciplinary Research Center on Biology and Chemistry, Center for Excellence in Molecular Synthesis, Shanghai Institute of Organic Chemistry, Chinese Academy of Sciences, 201203 Shanghai, China.
Ting MiInterdisciplinary Research Center on Biology and Chemistry, Center for Excellence in Molecular Synthesis, Shanghai Institute of Organic Chemistry, Chinese Academy of Sciences, 201203 Shanghai, China.
Hong ZhuLudwig Cancer Center, Harvard Medical School, Boston, MA 02115.
Junying YuanInterdisciplinary Research Center on Biology and Chemistry, Center for Excellence in Molecular Synthesis, Shanghai Institute of Organic Chemistry, Chinese Academy of Sciences, 201203 Shanghai, China; junying_yuan@hms.harvard.edu zhujd@sioc.ac.cn.ORCID 0000-0003-2405-6036
Jidong ZhuInterdisciplinary Research Center on Biology and Chemistry, Center for Excellence in Molecular Synthesis, Shanghai Institute of Organic Chemistry, Chinese Academy of Sciences, 201203 Shanghai, China; junying_yuan@hms.harvard.edu zhujd@sioc.ac.cn.
Chinese Academy of Sciences · CNHarvard University · US

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Protooncogene

Indexed as

Drug Delivery SystemsAnimalsAntineoplastic AgentsCell Cycle ProteinsCell Line, TumorHumansInhibitor of Apoptosis ProteinsMiceNeoplasmsNuclear ProteinsProto-Oncogene Proteins c-mycUbiquitinationXenograft Model Antitumor AssaysAntineoplastic AgentsCell Cycle ProteinsInhibitor of Apoptosis ProteinsMAD1L1 protein, humanMYC protein, humanNuclear ProteinsProto-Oncogene Proteins c-mycapoptosiscIAP1MAD1MYCubiquitination

Identifiers

PMID30181285
PMCPMC6176641
OpenAlexW2890576154

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.